Search
For optimal search results, please limit to 2 product keywords
If you are searching for information related to a product:
- For optimal results, please enter at least 2 search terms in addition to product name
- Example: [product name] [search term] [search term]
- Example: Product + clinical trials
- For an exact match, please include search terms in double quotations. For example: "Elevatum"
IV = Intravenous, SC = Subcutaneous
Safety Data Sheets:
Tecentriq® Healthcare Provider Letters:
Mechanism of Action
Tecentriq® Mechanism of Action
Looking for more information?
Reach out to a Genentech Medical Science Liaison near you, or connect with the contact center.
Call Us: 1-800-821-8590 Hours: Monday-Friday, 5am-5pm PT
Learn more about Tecentriq Hybreza™
Tecentriq Hybreza Dosing
Dosing Information
To view a PDF of the above document, please click here.
Looking for more information?
Reach out to a Genentech Medical Science Liaison near you, or connect with the contact center.
Call Us: 1-800-821-8590 Hours: Monday-Friday, 5am-5pm PT
Publications and Congresses
The information in this section may include content beyond what is in the FDA-approved label. Because the FDA has not approved such content, no conclusions regarding safety or efficacy may be made. Providing this information should not be construed as recommendation for use of a Genentech product for unapproved uses. For FDA-approved products please consult the product’s full prescribing information for a complete discussion of risks and benefits of the product(s) for its approved indication(s).
Publications: The list of publications is not an exhaustive list of published materials on the product. The list of references by data topics is selected per evidence-based medicine criteria. To browse a full listing of published scientific literature:
Congresses: The list of congresses is a subset of Roche/Genentech posters and oral presentations for the product with data presented at scientific meetings in the recent 24 months. To browse full Roche/Genentech congress presentations and posters:
Clinical Practice Guidelines
* This material is being provided to you in compliance with the FDA Guidance on Scientific Information on Unapproved Uses (SIUU).
- This clinical practice guideline includes information that is not found in the approved product labeling for Genentech products, and may therefore reference uses for which safety and effectiveness has not yet been established. Individual treatment decisions should be made based upon the prescribing physician’s determination of the benefits and risk.
- Reimbursement under public and private health care programs may not be available for unapproved product use. It is your responsibility to check applicable reimbursement policies before submitting claims for coverage.
- The opinions expressed in this clinical practice guideline do not necessarily reflect those of Genentech. Readers are encouraged to contact the National Comprehensive Cancer Network® (NCCN®) at https://www.nccn.org/home/about/contact-us with questions regarding the content of the clinical practice guidelines.
- You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch, or to Genentech at (888) 835-2555.
- Please see https://www.gene.com/medical-professionals/medicines for the full prescribing information for Genentech products.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Colon Cancer
The NCCN Guidelines® for Colon Cancer have recently been updated to include clinical considerations for the adjuvant treatment of patients with deficient mismatch repair (dMMR)/microsatellite instability-high (MSI-H) colon cancer.
A free account is required to access the guidelines. The guidelines can be found under Guidelines>> Treatment by Cancer Type>> Colon Cancer